Abstract: Disclosed herein are compositions, kits and methods for treating and detecting cancer, and more particularly radiolabeled conjugates used for targeted radiotherapy of cancer patients.
Abstract: The invention provides D02S derivatives conjugated to monosaccharide ligands directly or through a linker and optionally chelated to a metal, wherein the D02S derivatives having the following structure: wherein R1?, R2? are each independently —OH or —O-alkyl; R1 is a hydrogen, a linker, or a ligand; R3 is a linker and/or a ligand; and n is an integer from 1 to 10; the linker is an amino acid, a peptide, an amino alcohol, a polyethylylene glycol, an alkyl, an alkenyl, an alkynyl, an azide, an aromatic compound, a carboxylic acid, or an ester, the alkyl, alkenyl, or alkynyl is optionally substituted with an alkyl, a halogen, a nitro group, a hydroxyl group, an amino group, or a carboxyl group; the ligand is a GLUT1 targeting moiety.
Type:
Grant
Filed:
June 20, 2012
Date of Patent:
January 24, 2017
Assignee:
RadioMedix Inc.
Inventors:
Izabela Tworowska, Jennifer Sims-Mourtada, Ebrahim S. Delpassand
Abstract: The present invention relates to the field of radiochemistry, nuclear imaging, radionuclide therapy and chemical synthesis. More particularly, it concerns a strategy for radiolabeling target ligands. It further concerns methods of using those radiolabeled ligands for imaging, radionuclide therapy and tissue-specific disease imaging.
Type:
Grant
Filed:
March 27, 2008
Date of Patent:
August 9, 2016
Assignee:
Radiomedix, Inc.
Inventors:
Ali Azhdarinia, Ebrahim S. Delpassand, Izabela Tworowska, Jennifer Sims-Mourtada
Abstract: The invention provides D02S derivatives conjugated to monosaccharide ligands directly or through a linker and optionally chelated to a metal, wherein the D02S derivatives having the following structure: wherein R1?, R2? are each independently —OH or —O-alkyl; R1 is a hydrogen, a linker, or a ligand; R3 is a linker and/or a ligand; and n is an integer from 1 to 10; the linker is an amino acid, a peptide, an amino alcohol, a polyethylylene glycol, an alkyl, an alkenyl, an alkynyl, an azide, an aromatic compound, a carboxylic acid, or an ester, the alkyl, alkenyl, or alkynyl is optionally substituted with an alkyl, a halogen, a nitro group, a hydroxyl group, an amino group, or a carboxyl group; the ligand is a GLUT1 targeting moiety.
Type:
Application
Filed:
June 20, 2012
Publication date:
August 14, 2014
Applicant:
RadioMedix Inc.
Inventors:
Izabela Tworowska, Jennifer Sims-Mourtada, Ebrahim S. Delpassand
Abstract: The present invention concerns methods and compositions related to a chelator and a HHRT ligand. In specific embodiments of the invention the chelator is conjugated to the HHRT ligand. In another specific embodiment of the invention, the chelator is chelated to a metal. In a particular embodiment of the invention, there is a metal species that is chelated to a chelator, which is then directly or indirectly conjugated to a HHRT ligand. In some embodiments, the composition further comprises a therapeutic agent. In particular cases, the compositions are employed for cancer diagnosis and/or therapy.
Type:
Application
Filed:
February 27, 2009
Publication date:
December 16, 2010
Applicant:
RADIOMEDIX INC.
Inventors:
Jennifer Sims-Mourtada, Ali Azhdarinia, Izabela Tworowska, Hitomi Saso